Cosmos Health Introduces High-Vote Series B Preferred, Elects Directors at Annual Meeting

summarizeSummary

Cosmos Health shareholders approved a new Series B Preferred Stock with 100 million votes and elected six directors at the 2026 annual meeting. The preferred shares carry no economic rights, serving solely as a voting control mechanism.

check_boxKey Events · Corporate Governance and Compliance · COSM

• Series B Preferred Stock Approved

  Shareholders approved 100,000 shares of Series B Preferred Stock with 1,000 votes per share (100 million total votes), no dividends, no conversion, and a $0.001 liquidation preference — a pure voting control mechanism.

• Directors Elected

  Six directors were elected: Grigorios Siokas, Demetrios G. Demetriades, John J. Hoidas, Dr. Anastasios Aslidis, Suhel Bhutawala, and Theodoros C. Karkantzos, each receiving over 79% affirmative votes.

• Auditor Ratified

  The appointment of the independent registered public accounting firm was ratified with 84.24% approval.

• 2026 Equity Omnibus Plan Approved

  The 2026 Equity Omnibus Plan was approved with 79.58% of votes, enabling future equity-based compensation.

auto_awesomeAnalysis · COSM · Trade & Services

Shareholders of Cosmos Health approved a new Series B Preferred Stock carrying 100 million total votes — 1,000 votes per share — giving the board a powerful tool to control corporate outcomes without economic dilution. The 100,000 designated shares carry no dividends, no conversion rights, and a liquidation preference of just $0.001 per share, making them purely a voting mechanism. This move comes against a backdrop of a going-concern warning, a $100 million ATM program, and a recent $5 million buyback authorization — a governance step that could entrench management or facilitate a defensive strategy. The annual meeting also elected six directors and ratified the auditor, with all proposals passing by wide margins.